Febuxostat

Febuxostat
Clinical data
Trade namesUloric, Adenuric, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa609020
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability≥84% absorbed
Protein binding99.2% to albumin
Metabolismvia CYP1A1, 1A2, 2C8, 2C9, UGT1A1, 1A8, 1A9[5]
Elimination half-life~5–8 hours
ExcretionUrine (~49%, mostly as metabolites, 3% as unchanged drug); feces (~45%, mostly as metabolites, 12% as unchanged drug)
Identifiers
IUPAC name
  • 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-
    1,3-thiazole-5-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.207.329
Chemical and physical data
FormulaC16H16N2O3S
Molar mass316.38 g·mol−1
3D model (JSmol)
SMILES
  • N#Cc1c(OCC(C)C)ccc(c1)c2nc(c(s2)C(=O)O)C
InChI
  • InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20) Y
  • Key:BQSJTQLCZDPROO-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

Febuxostat, sold under the brand name Uloric among others, is a medication used long-term to treat gout due to high uric acid levels.[6] It is generally recommended only for people who cannot take allopurinol.[7][8] It is taken by mouth.[6]

Common side effects include liver problems, nausea, joint pain, and a rash.[6] Serious side effects include an increased risk of death as compared with allopurinol, Stevens–Johnson syndrome, and anaphylaxis.[8][7] Use is not recommended during pregnancy or breastfeeding.[8] It inhibits xanthine oxidase, thus reducing production of uric acid in the body.[6]

Febuxostat was approved for medical use in the European Union in 2008,[4] and in the United States in 2009.[6] A generic version was approved in 2019.[9][10]

  1. ^ Cite error: The named reference drugnames was invoked but never defined (see the help page).
  2. ^ "Febuxostat (Uloric) Use During Pregnancy". Drugs.com. 22 February 2019. Retrieved 17 May 2020.
  3. ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  4. ^ a b "Adenuric EPAR". European Medicines Agency (EMA). 21 April 2008. Retrieved 14 September 2024.
  5. ^ Cite error: The named reference EMA was invoked but never defined (see the help page).
  6. ^ a b c d e "Febuxostat Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 February 2019.
  7. ^ a b "Drug Safety and Availability - FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)". FDA. 21 February 2019. Retrieved 26 February 2019.
  8. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1087. ISBN 9780857113382.
  9. ^ "Generic Uloric Availability". Drugs.com. Retrieved 1 August 2019.
  10. ^ "Febuxostat Generic Uloric". Retrieved 15 April 2020.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.